SCHEMBL1973559

SCHEMBL1973559

CCCn1c(C)c(C(=O)N[C@@H](CC)c2ccccc2)c(C)c(Br)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 15/20 0.47
TACR2 P21452 6/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
NFKB1 P19838 1/20 0.46
MAPK1 P28482 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974595 0.89 PPARG (0.43) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1976721 0.89 PKM (0.41) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1974267 0.88 TACR3 (0.41) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1974261 0.88 PPARG (0.41) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1974280 0.86 ALDH1A1 (0.46) TACR3TACR2ALDH1A1MEN1TP53
SCHEMBL1974417 0.85 CYP26A1 (0.40) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL2154650 0.84 TACR3 (0.50) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1975975 0.83 RIPK1 (0.43) TACR3ALDH1A1CYP2C9MEN1MAPK1
SCHEMBL1973564 0.83 TACR3 (0.46) TACR3TACR2ALDH1A1TSHRCYP1A2
SCHEMBL1975472 0.82 SMYD3 (0.41) TACR3ALDH1A1MEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011072691-A1 PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-06-23 WO claimed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US claimed
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
US-8207347-B2 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-06-26 US disclosed
WO-2011072691-A1 PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-06-23 WO disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed
US-20110144164-A1 Pyridone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144164-A1 Pyridone derivatives as NK3 antagonists KCNK3, GRIK3, KCND3 TACR3 26/4885TACR2 32/4885ALDH1A1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.